Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32002
Title: | GABAA receptor neurotransmission & epilepsy: principles, disease mechanisms & pharmacotherapy. | Austin Authors: | Bryson, Alexander ;Reid, Christopher;Petrou, Steven | Affiliation: | The Florey Institute of Neuroscience and Mental Health The University of Melbourne, Parkville, VIC 3052, Australia Neurology Praxis Precision Medicines, Inc., Cambridge, MA 02142, USA |
Issue Date: | 22-Jan-2023 | Date: | 2023 | Publication information: | Journal of Neurochemistry 2023; 165(1) | Abstract: | Epilepsy is a common neurological disorder associated with alterations of excitation-inhibition balance within brain neuronal networks. GABAA receptor neurotransmission is the most prevalent form of inhibitory neurotransmission and is strongly implicated in both the pathophysiology and treatment of epilepsy, serving as a primary target for antiseizure medications for over a century. It is now established that GABA exerts a multifaceted influence through an array of GABAA receptor subtypes that extends far beyond simply negating excitatory activity. As the role of GABAA neurotransmission within inhibitory circuits is elaborated, this will enable the development of precision therapies that correct the network dysfunction underlying epileptic pathology. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32002 | DOI: | 10.1111/jnc.15769 | ORCID: | 0000-0002-0033-8197 |
Journal: | Journal of Neurochemistry | PubMed URL: | 36681890 | ISSN: | 1471-4159 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.